On April 24, the preprint of the lancet was published under the title of "predictive value of the neutral to lymphocyte ratio (NLR) for diagnosis and worse clinical course of the coved-19: findings from ten provinces in According to the novel coronavirus pneumonia, the "Qingfei detoxification Decoction" emergency team based on 662 cases of clinical observation in ten provinces, the study found that neutrophil lymphocyte ratio (NLR) has important predictive value for the diagnosis of new crown pneumonia (COVID-19) and the clinical progress of severe patients in China.

The novel coronavirus pneumonia is the first Chinese medicine research team to publish its clinical research results since the outbreak of the new crown pneumonia outbreak in the world. The first corresponding author of this paper is Wang Yongyan, honorary president of Chinese Academy of traditional Chinese medicine and academician of Chinese Academy of engineering.

Based on the novel coronavirus pneumonia clinical practice of multicenter and large sample, the study systematically observed the patients who were treated with Qingfei detoxification decoction, and scientifically and statistically analyzed the physical and chemical indexes of clinical characteristics of COVID-19 patients, and objectively analyzed the relative clinical value. The study is divided into two stages: the first stage is a retrospective single center cohort study in Heilongjiang, involving 88 patients; the second stage is a retrospective, multi center, large sample study, involving 635 patients (including 61 patients in the first stage) from 43 institutions in 10 provinces. All patients were treated with Qingfei Paidu decoction, which has been cured and discharged.

Novel coronavirus pneumonia ratio (NLR) is a new predictor of neutrophil pneumonia in patients with viral pneumonia. According to statistics, novel coronavirus pneumonia has increased the risk of COVID-19 by 1.752 times per unit. This has important diagnostic value for early identification of COVID-19. Especially when the condition of nucleic acid detection is insufficient, the observation can promote early detection of new crown pneumonia and remind the corresponding prevention strategy. At present, positive nucleic acid test is the "gold standard" for the diagnosis of covid-19, but there are still problems such as uneven distribution of nucleic acid detection resources, different detection conditions and abilities, interference of detection accuracy, false negative test results and so on. Novel coronavirus pneumonia is very useful for early detection of new crown pneumonia. According to PubMed, as of April 2, the research team had no relevant research report in the world.

Another important finding of this paper is that NLR ≥ 4.06 and lymphocyte ≤ 0.765 can be used as the prediction index of heavy covid-19. Novel coronavirus pneumonia patients were diagnosed with increased risk of light to normal, and the risk of light to severe was increased 1.342 times in the treatment of newly diagnosed crown pneumonia patients, NLR found. Therefore, novel coronavirus pneumonia patients' clinical treatment strategies are important for improving the cure rate and reducing the mortality rate.

It is reported that novel coronavirus pneumonia emergency treatment team launched the clinical treatment study in four provinces in Hebei, Shanxi, Heilongjiang and Shaanxi in January 27th. In February 6th, according to the data of 214 cases of good clinical efficacy of the project group, the national health and Health Commission and the State Administration of traditional Chinese Medicine jointly launched the recommendation to use Qingfei detoxification Decoction in the treatment of new crown pneumonia in the integrative medicine; in February 25th, the national health service was launched. The novel coronavirus pneumonia, the Ministry of health and social security and the State Administration of traditional Chinese medicine awarded the team the title of "advanced group of the national health and health system, new prevention and control of pneumonia". The team members include Chinese and Western medicine experts from the Institute of clinical basic medicine of the Chinese Academy of traditional Chinese medicine, Beijing University of traditional Chinese medicine, the First Affiliated Hospital of Guangzhou University of traditional Chinese medicine, Guang'anmen Hospital of the Chinese Academy of traditional Chinese medicine, and 66 hospitals in 10 provinces including Shanxi, Heilongjiang, Shaanxi, Hebei, Anhui, Sichuan, Fujian, Chongqing, Guangxi and Qinghai."Qingfei Paidu Decoction" related research results will be published one after another.

Soure:http://www.cntcm.com.cn/2020-04/28/content_74803.htm

Time:2020.4.28